StephN
11-20-2007, 08:02 PM
Tanespimycin (was known as KOS-953) is taken with Herceptin. One drawback is that you can't have had a regimen that included Herceptin. This drug is used for multiple myloma and other conditions, and may be avail off label.
Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.
I am posting this as it seems to have gone under the radar of the clinical trial sleuths we have here.
Definition from the National Cancer Institute:
tanespimycin
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells. Check for active clinical trials (http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1) or closed clinical trials (http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1&closed=1) using this agent. (NCI Thesaurus (http://nciterms.nci.nih.gov/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37899))
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity In Phase 2 Trial Of Patients With HER2-Positive Metastatic Breast Cancer
Link to the info from San Antonio last year - I am sure there will be an update this year:
http://www.medicalnewstoday.com/articles/59083.php
I have a friend here who is on this trial - she was number 7 enrolled. She says there are now some 40 women enrolled and the trial has more sites. She has tumors in unusual places (on aorta for one) and during her neoadjuvent treatment her primary tumor grew from 1.5 to 8 cm and metastesized. Her disease is VERY agressive and hard to halt. In a little over a year her tumors have shrunk and nothing new. She keeps her hair and can still work.
Just wanted to mention this as some here are seeking new treatment for advancing disease and here is something with a new twist, working against the heat shock protein as well as HER2 pathways.
Tanespimycin is an Hsp90 inhibitor that has demonstrated the potential to disrupt the activity of multiple oncogenes and cell signaling pathways implicated in tumor growth, including HER2, a key pathway in breast cancer.
I am posting this as it seems to have gone under the radar of the clinical trial sleuths we have here.
Definition from the National Cancer Institute:
tanespimycin
A benzoquinone antineoplastic antibiotic derived from the antineoplastic antibiotic geldanamycin. Tanespimycin binds to and inhibits the cytosolic chaperone functions of heat shock protein 90 (HSP90). HSP90 maintains the stability and functional shape of many oncogenic signaling proteins; the inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins that may be overexpressed by tumor cells. Check for active clinical trials (http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1) or closed clinical trials (http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=43635&idtype=1&closed=1) using this agent. (NCI Thesaurus (http://nciterms.nci.nih.gov/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C37899))
Kosan's Hsp90 Inhibitor, Tanespimycin, Shows Promising Antitumor Activity In Phase 2 Trial Of Patients With HER2-Positive Metastatic Breast Cancer
Link to the info from San Antonio last year - I am sure there will be an update this year:
http://www.medicalnewstoday.com/articles/59083.php
I have a friend here who is on this trial - she was number 7 enrolled. She says there are now some 40 women enrolled and the trial has more sites. She has tumors in unusual places (on aorta for one) and during her neoadjuvent treatment her primary tumor grew from 1.5 to 8 cm and metastesized. Her disease is VERY agressive and hard to halt. In a little over a year her tumors have shrunk and nothing new. She keeps her hair and can still work.
Just wanted to mention this as some here are seeking new treatment for advancing disease and here is something with a new twist, working against the heat shock protein as well as HER2 pathways.